3-Acetyl-2-hydroxybenzimidic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Acetyl-2-hydroxybenzimidic acid
• 英文别名: 3-acetyl-2-hydroxybenzamide
• 化学式: C₉H₉NO₃
• 分子量: 179.17
• InChiKey: KRVFRXXJCPDPFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Thalidomide analogs
  申请人：Greig H. Nigel

  公开号：US20060211728A1

  公开（公告）日：2006-09-21

  Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

  本文披露了调节肿瘤坏死因子α（TNF-α）活性和血管生成的沙利度胺类似物。特别是，本文披露了等构硫含类沙利度胺类似物。同时还披露了使用这些类似物治疗受试者的方法。
• THALIDOMIDE ANALOGS
  申请人：Greig Nigel H.

  公开号：US20110245210A1

  公开（公告）日：2011-10-06

  Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

  本文披露了调节肿瘤坏死因子α（TNF-α）活性和血管生成的沙利度胺类似物。在特别披露的实施例中，沙利度胺类似物是同位素硫含量类似物。还披露了使用这些类似物治疗受试者的方法。
• Thalidomide Analogs
  申请人：Greig Nigel H.

  公开号：US20130035363A1

  公开（公告）日：2013-02-07

  Thalidomide analogs that modulate tumor necrosis factor alpha (TNFα) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

  本发明揭示了调节肿瘤坏死因子α（TNFα）活性和血管生成的沙利度胺类似物。特别是，本发明揭示的沙利度胺类似物是等构硫含有的类似物。本发明还揭示了使用这些类似物治疗受试者的方法。
• Endovascular catheters and methods for carotid body ablation
  申请人：Gelfand Mark

  公开号：US10219855B2

  公开（公告）日：2019-03-05

  Systems, devices, and methods for treating a patient having a sympathetically mediated disease associated at least in part with augmented peripheral chemoreflex or heightened sympathetic activation. The treatments include ablating one or more peripheral chemoreceptors or associated afferent nerves to reduce or remove afferent neural signals from the peripheral chemoreceptor.

  用于治疗交感神经介导疾病患者的系统、设备和方法，该疾病至少部分与外周化学感受器增强或交感神经激活增强有关。治疗方法包括消融一个或多个外周化学感受器或相关传入神经，以减少或消除来自外周化学感受器的传入神经信号。
• THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS
  申请人：THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES

  公开号：EP1663223A2

  公开（公告）日：2006-06-07